| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 1085910 | Le Pharmacien Hospitalier | 2008 | 14 Pages |
Abstract
The marketing authorization of new treatments improves everyday the forecast of systemic fungal infections. The respect of the good use of these treatments is one of the keys of therapeutic success and of the control of treatment costs.
Related Topics
Health Sciences
Pharmacology, Toxicology and Pharmaceutical Science
Pharmacology, Toxicology and Pharmaceutics (General)
Authors
Sébastien Hochart, Frédérique Barrier, Isabelle Durand-Joly, Sandrine Horrent, Bertrand Decaudin, Pascal Odou,